# Boltz Raises $110 Million to Build Its Pharmaceutical AI Business

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/61670
Published: 2026-11-19T21:19:53.000Z
Updated: 2026-11-19T21:19:53.000Z
Section: Business

> The Series A, led by Bessemer, will support headcount growth and additional computing infrastructure.

Boltz PBC raised $110 million in a Series A led by Bessemer, giving the pharmaceutical AI startup funding to grow its headcount and add computing infrastructure.

Greycroft, Andreessen Horowitz, Amplify Partners, F-Prime Capital, Hummingbird and other new and returning investors joined the round. Boltz announced the financing Wednesday.

The company develops artificial intelligence models for pharmaceutical researchers. Its BoltzMol-1 model evaluates a smaller set of promising small molecules to generate binding-affinity data, which helps researchers assess how strongly a molecule may bind to a biological target.

Boltz’s BoltzProt-1 model generates protein designs using data from small-molecule hits, then reviews each design for potential use in drug development.


